Ibotta (NYSE:IBTA) 株価情報

IBOTTA INC-CL A

Ibotta

Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).

Ibotta Inc

Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) reported quarterly losses of $(4.25) per share which missed the analyst consensus estimate of $(3.56) by 19.38 percent. This is a 38.94 percent increase over losses of $(6.96) per share from the same period last year.

Earnings

News

ELTX

Elicio Therapeutics FY 2024 GAAP EPS $(4.25) Misses $(3.56) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $17.6M. Including $10M In Gross Proceeds From January 2025 Registered Direct Offering, The Company Expects Cash Runway Into Q4 2025

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) with a Buy and maintains $30 price target.

Price Target

Reiteration

Analyst Ratings

TYRA

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target

Gyre Therapeutics ("Gyre") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People's Republic of China ("PRC") has approved its clinical trial application for a potential new indication for pirfenidone in oncology-related pulmonary complications. The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP).
This regulatory milestone marks the expansion of pirfenidone beyond its established role in idiopathic pulmonary fibrosis (IPF) into the oncology supportive care space, offering a novel lung-protective strategy for cancer patients undergoing radiation therapy or immunotherapy.
In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's potential in this new indication.
Radiation-Induced Lung Injury (RILI): Radiation therapy is a cornerstone of lung cancer treatment. However, 5%–25% of patients experience lung damage due to radiation exposure, limiting the ability to escalate doses and thereby compromising treatment efficacy.
Checkpoint Inhibitor Pneumonitis (CIP): Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but 13%–19% of patients develop CIP. This condition accounts for approximately 35% of immune-related adverse event (irAE) deaths and often necessitates treatment discontinuation.
Currently, no targeted therapies exist for lung injuries caused by radiation or immunotherapy. Distinguishing between RILI and CIP is challenging, particularly when both occur concurrently. Corticosteroids remain the standard of care despite significant long-term side effects. By targeting and inhibiting fibrotic pathways, pirfenidone may address the root cause of lung injury progression, offering a new treatment option for patients receiving radiation or immunotherapy.

GYRE

Gyre Gets Green Light for Trial Aiming to Protect Cancer Patients' Lungs During Treatment

Shares of Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>), an energy infrastructure company that supports large-scale computing needs, including Bitcoin mining and high-performance computing, are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Monday.
The company has unveiled American Bitcoin Corp., a new subsidiary dedicated to large-scale Bitcoin mining and strategic reserve accumulation.
The development comes after Hut 8 contributed the majority of its ASIC miners in return for a dominant stake in a project supported by Eric Trump and Donald Trump Jr. The initiative was <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44556534/hut-8-and-eric-trump-launch-american-bitcoin-to-set-a-new-standard-in-bitcoin-mining" rel="noreferrer noopener">subsequently renamed American Bitcoin.</a>
The newly launched company aims to become the world&#8217;s most efficient dedicated Bitcoin miner. As part of this shift, all Bitcoin mining activities previously managed under Hut 8&#8217;s Compute segment will now operate under the American Bitcoin name.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/03/44532830/rocket-lab-joins-us-space-forces-5-6-billion-launch-program-stock-soars" rel="noreferrer noopener">Rocket Lab Joins US Space Force&#8217;s $5.6 Billion Launch Program; Stock Soars</a>
Initially, American Bitcoin&#8217;s financial performance will be reflected within Hut 8&#8217;s consolidated reports.
Meanwhile, Hut 8 will continue as its sole infrastructure and operations partner, establishing long-term commercial agreements designed to ensure consistent revenue generation.
&#8220;From the start, we&#8217;ve backed our conviction in Bitcoin—personally and through our businesses,&#8221; said Donald Trump Jr.
&#8220;But simply buying Bitcoin is only half the story. Mining it on favorable economics opens an even bigger opportunity. We&#8217;re excited to bring investors into that equation through a platform engineered to execute on this thesis and deliver real, tangible participation in Bitcoin&#8217;s growth.&#8221;
American Bitcoin aims to achieve a computing capacity exceeding 50 exahashes per second (EH/s) while keeping its fleet efficiency under 15 joules per terahash (J/TH), with a goal of becoming a publicly listed company.
The company&#8217;s leadership team will include Mike Ho as Executive Chairman, Matt Prusak as CEO, and Eric Trump as Chief Strategy Officer. The Board of Directors will feature Ho, Asher Genoot, Justin Mateen, and Michael Broukhim.
Under long-term agreements, Hut 8 will provide colocation services, operational management, and other support functions for American Bitcoin. The parent company will oversee daily operations through a shared services contract.
Price Action: HUT shares traded higher by 7.08% at $12.55 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44533913/lockheed-martin-and-google-partner-to-advance-ai-in-defense" target="_blank" rel="noreferrer noopener">Lockheed Martin And Google Partner To Advance AI In Defense</a></li>
</ul>
Image via Shutterstock.

Equities

Movers

General

President Trump's Sons Partner With Hut 8 To Unveil American Bitcoin For Large-Scale Bitcoin Mining

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Niagen Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAGE#NASDAQ">NAGE</a>) with a Buy and maintains $11 price target.

NAGE

HC Wainwright & Co. Reiterates Buy on Niagen Bioscience, Maintains $11 Price Target

USAR

USA Rare Earth Deploys Advanced Innovations Lab At Oklahoma Manufacturing Facility

Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from the same period last year.

CABA

Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) with a Buy and maintains $20 price target.

TRDA

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) with a Buy and maintains $20 price target.

ACOG

HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $20 Price Target

EVTL

Vertical Aerospace To Adopt Combined Charging Standard (CCS) To Boost eVTOL Deployment

Chicago Atlantic BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIEN#NASDAQ">LIEN</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.29 by 20.69 percent. This is a 25 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $12.65 million which beat the analyst consensus estimate of $11.00 million by 14.98 percent. This is a 251.33 percent increase over sales of $3.60 million the same period last year.

Earnings Beats

LIEN

Chicago Atlantic BDC Q4 Net Investment Income per share  $0.35 Beats $0.29 Estimate, Total investment income $12.65M Beat $11.00M Estimate

GORV

Lazydays Signs Letter Of Intent To Divest Three Store Locations To General RV Center

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $42 price target.

AVXL

HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $42 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) with a Buy and raises the price target from $70 to $100.

SLNO

HC Wainwright & Co. Maintains Buy on Soleno Therapeutics, Raises Price Target to $100

On Friday, March 28th, U.S. markets closed sharply lower as fears of slowing economic growth, rising inflation, and escalating tariffs under the Trump administration weighed on markets. Major tech stocks like Amazon, Microsoft, and Apple tumbled.
Consumer spending disappointed, inflation expectations surged, and investors grew cautious ahead of new tariffs. Markets anticipate possible interest rate cuts by the Federal Reserve.
In economic data, the Fed&#8217;s preferred inflation gauge — the core PCE price index — rose 2.8% year-over-year in February, above the 2.7% forecast. Investor concerns grew as the University of Michigan survey showed 5-year inflation expectations rising to 4.1%, the highest since February 1993.
Most S&amp;P 500 sectors ended lower, led by losses in consumer discretionary, communication services, and tech stocks. Utilities were the exception, closing higher and defying the broader market downturn.
The Dow Jones Industrial Average was down 1.69% at 41,583.90, the S&amp;P 500 slid 1.97% to 5,580.94, and the Nasdaq Composite fell 2.70% to 17,322.99.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 closed the session drastically lower by 4.03% at 35,624.50, led by losses in the Shipbuilding, Manufacturing, and Services sectors.</li>
<li>Japan&#8217;s Nikkei 225 plunged 4.05%, entering correction territory with a nearly 12% drop from its December peak, driven by fears over U.S. tariffs.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 was down 1.74% and closed at 7,843.40, led by losses in the Metals &amp; Mining, Resources and Materials sectors.</li>
<li>India markets closed for the Ramzan (Id-Ul-Fitar) holiday.</li>
<li>China&#8217;s Shanghai Composite declined 0.46% to 3,335.75, and the Shanghai Shenzhen CSI 300 slid 0.71% to 3,887.31.</li>
<li>Hong Kong&#8217;s Hang Seng was down 1.31%, ending the session at 23,119.58.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 was down 1.37%.</li>
<li>Germany&#8217;s DAX declined 1.27%.</li>
<li>France&#8217;s CAC slid 1.37%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.98%.</li>
<li>European stocks fell sharply as investors braced for U.S. tariffs, which are set to take effect Wednesday. Fears of broader trade measures raised recession risks and pressured global markets and oil prices.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.23% at $69.52/bbl, and Brent was up 0.23% at $72.93/bbl.</li>
<li>Oil prices rose after Trump threatened 25–50% tariffs on Russian oil buyers, but gains were limited as traders doubted the seriousness of the move. Analysts cited market fatigue over U.S. sanctions talk.</li>
<li>Natural Gas rose 03.12% to $4.192.</li>
<li>Gold was trading higher by 1.02% at $3,146.11, Silver was up 0.15% to $34.868, and Copper slid 1.80% to $5.0375.</li>
<li>Gold surged to a record high on Monday, marking its third straight session of gains, as investors sought safety amid rising tariff uncertainty and inflation fears.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.59%, S&amp;P 500 futures declined 0.87% and Nasdaq 100 futures fell 1.25%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index fell 0.22% to 104.03, USD/JPY was down 0.44% to 149.17, and USD/AUD gained 0.57% to 1.5990.</li>
<li>The U.S. dollar held steady Monday but is set for a quarterly loss of over 4% amid fears that Trump&#8217;s tariff plans will stoke inflation and hurt growth.</li>
</ul>
Image via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Japan's Index Falls In Correction Territory, Europe Declines On Trade Fears; Gold Surges To New Record - Global Markets Today While US Slept

Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.50) by 12 percent. This is a 56.25 percent increase over losses of $(1.28) per share from the same period last year.

UNCY

Unicycive Therapeutics FY 2024 GAAP EPS $(0.56) Misses $(0.50) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Of $26.1M, Sufficient To Fund Planned Operations Into 2026

D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) ("D-Wave" or the "Company"), a leader in quantum computing systems, software, and services, and Ford Otosan, a joint venture between Ford Motor Company and Koç Holding in Turkey, today announced that the vehicle manufacturer has deployed a hybrid-quantum application in production, streamlining manufacturing processes for its Ford Transit line of vehicles. The application, which uses D-Wave's annealing quantum computing technology, has improved vehicle production sequencing at Ford Otosan, a powerful demonstration of quantum computing's real-world impact in automotive manufacturing.

QBTS

Ford Otosan Uses Quantum Tech from D-Wave to Speed Up Transit Van Production

Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) reported quarterly losses of $(11.23) per share which missed the analyst consensus estimate of $(10.01) by 12.19 percent. This is a 49.21 percent increase over losses of $(22.11) per share from the same period last year. The company reported quarterly sales of $15.77 million which missed the analyst consensus estimate of $17.00 million by 7.26 percent. This is a 13.05 percent decrease over sales of $18.13 million the same period last year.

Earnings Misses

VERO

Venus Concept Q4 2024 GAAP EPS $(11.23) Misses $(10.01) Estimate, Sales $15.77M Miss $17.00M Estimate

LM Funding America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) reported quarterly losses of $(0.86) per share. This is a 28.36 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $1.985 million which beat the analyst consensus estimate of $1.500 million by 32.33 percent. This is a 51.05 percent decrease over sales of $4.055 million the same period last year.

LMFA

LM Funding America Q4 2024 GAAP EPS $(0.86) Down From $(0.67) YoY, Sales $1.985M Beat $1.500M Estimate

Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) reported quarterly losses of $(2.39) per share. This is a 119.27 percent decrease over losses of $(1.09) per share from the same period last year. The company reported $159.88 million in sales this quarter. This is a 19.26 percent decrease over sales of $198.03 million the same period last year.

Lazydays Hldgs Q4 EPS $(2.39) Down From $(1.09) YoY, Sales $159.88M Down From $198.03M YoY

Press Releases

IBTA Investors Have Opportunity to Lead Ibotta, Inc. Securities Fraud Lawsuit

Legal

Ibotta, Inc. Investor News: If You Have Suffered Losses in Ibotta, Inc. (NASDAQ: IBTA) You Are Encouraged to Contact The Rosen Law Firm About Your Rights

IBTA INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Ibotta, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Johnson Fistel, PLLP's Denver Office Continues Investigation into Ibotta, Inc. on Behalf of Shareholders Who Incurred Losses

Bragar Eagel & Squire, P.C. Is Investigating Fortrea and Ibotta and Encourages Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ibotta, Inc. - IBTA

Ibotta, Inc. Investor News: If You Have Suffered Losses in Ibotta, Inc. (NYSE: IBTA) You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Comments

Ibotta

ニュース

パートナーシップ

ベンジンガ・グローバル